Semler Scientific Appoints Renae Cormier as Chief Financial Officer

Semler Scientific, a renowned developer and manufacturer of innovative medical products and services, has recently announced the appointment of Ms. Renae Cormier as its Chief Financial Officer (CFO). Effective from July 10, 2023, Ms. Cormier will spearhead the company's accounting, finance, investor relations, and business strategy efforts. With a strong background in finance and accounting, Ms. Cormier brings extensive experience as an investment analyst and auditor to her new role. She will play a pivotal part in shaping Semler Scientific's financial strategy, enhancing operational efficiency, and supporting the company's ongoing growth and success.

‍

Semler Scientific Expects Record Quarterly Revenues in Q2 2023

Semler Scientific anticipates reporting its highest-ever quarterly revenues for the second quarter ending June 30, 2023. The exceptional performance is attributed to the continued sales of QuantaFlo®, a groundbreaking product used for testing peripheral arterial disease in both existing and new customers. The detailed financial information for this remarkable achievement will be provided in the second-quarter earnings release, which is expected to be announced around August 10, 2023.

‍

Strategic Streamlining Initiatives by Semler Scientific

Alongside the positive news of the new CFO and record revenues, Semler Scientific has announced a strategic plan to streamline its operations. By September 15, 2023, the company aims to reduce its employee headcount by approximately 30%. This proactive measure is driven by the goal of enhancing operational efficiency while maintaining high-quality service for its valued customers.

‍

Cost Estimates and Anticipated Impact

Semler Scientific estimates that the streamlining process will result in severance costs ranging from $0.7 million to $0.9 million. These costs, associated with one-time termination benefits, are expected to be paid by December 31, 2023. Furthermore, the company forecasts a reduction in quarterly operating expenses by approximately $1.5 million to $2.0 million during the fourth quarter ending December 31, 2023. This reduction in expenses will contribute to Semler Scientific's commitment to optimizing its financial performance.